These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 14551572)

  • 1. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
    Kim NN
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
    Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
    Werkström V; Svensson A; Andersson KE; Hedlund P
    BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
    Boolell M; Allen MJ; Ballard SA; Gepi-Attee S; Muirhead GJ; Naylor AM; Osterloh IH; Gingell C
    Int J Impot Res; 1996 Jun; 8(2):47-52. PubMed ID: 8858389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Berner MM; Kriston L; Harms A
    Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
    Roumeguère T; Sternon J; Schulman CC
    Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
    Park K; Moreland RB; Goldstein I; Atala A; Traish A
    Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
    Küthe A; Montorsi F; Andersson KE; Stief CG
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
    Bella AJ; Brant WO; Lue TF; Brock GB
    Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
    Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
    Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide regulation of penile erection: biology and therapeutic implications.
    Burnett AL
    J Androl; 2002; 23(5):S20-6. PubMed ID: 12236169
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.